Cross-tolerance Studies of Serotonin Receptors Involved in Behavioral Effects of LSD in Rats
Overview
Affiliations
Like hallucinogenic 5-HT2 agonists, LSD (d-lysergic acid diethylamide) produces characteristic decreases in locomotor activity and investigatory behaviors of rats tested in a novel environment. Because LSD is an agonist at both 5-HT1A and 5-HT2 receptors, however, the respective influences of these different receptors in the behavioral effects of LSD remain unclear. In particular, the paucity of selective 5-HT1A antagonists has made it difficult to assess the specific contribution of 5-HT1A receptors to the effects of LSD. An alternative approach to the delineation of receptor-specific effects is the use of cross-tolerance regimens. In the present studies, rats were pretreated with saline, 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT) (0.5 mg/kg SC), 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (1.0 mg/kg SC), or LSD (60 micrograms/kg SC), every 12 h for 5 or 8 days. Thirty-six hours later, rats were tested in a behavioral pattern monitor 10 min after injection of saline, 0.5 mg/kg 8-OH-DPAT, 1.0 mg/kg DOI, or 60 micrograms/kg LSD. As expected, tolerance to the decreases in locomotor activity produced by acute administrations of 8-OH-DPAT, DOI, or LSD occurred when rats were pretreated chronically with 8-OH-DPAT, DOI, or LSD, respectively. Furthermore, pretreatment with either 8-OH-DPAT or DOI produced cross-tolerance to LSD. These results support the hypothesis that the effects of LSD in this model reflect a combination of 5-HT1A and 5-HT2 effects and support the view that there is an interaction between 5-HT1A and 5-HT2 receptors.
Glennon R, Dukat M ACS Pharmacol Transl Sci. 2024; 7(6):1722-1745.
PMID: 38898956 PMC: 11184610. DOI: 10.1021/acsptsci.4c00157.
Inserra A, Piot A, De Gregorio D, Gobbi G CNS Drugs. 2023; 37(9):733-754.
PMID: 37603260 DOI: 10.1007/s40263-023-01008-5.
De Gregorio D, Popic J, Enns J, Inserra A, Skalecka A, Markopoulos A Proc Natl Acad Sci U S A. 2021; 118(5).
PMID: 33495318 PMC: 7865169. DOI: 10.1073/pnas.2020705118.
Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.
Sherwood A, Claveau R, Lancelotta R, Kaylo K, Lenoch K ACS Omega. 2020; 5(49):32067-32075.
PMID: 33344861 PMC: 7745443. DOI: 10.1021/acsomega.0c05099.
Schindler E, Wallace R, Sloshower J, DSouza D Front Pharmacol. 2018; 9:177.
PMID: 29545753 PMC: 5838010. DOI: 10.3389/fphar.2018.00177.